L ysophosphatidic acid (LPA), sphingosine-1-phosphate (S1P), and several other related molecules constitute a family of bioactive lipid phosphoric acids that function as receptor-active mediators to play important roles in cell growth, differentiation, apoptosis, and development. 1, 2 LPA and S1P are structurally simple glycero-and sphingo-phospholipids. LPA is a common intracellular intermediate in the synthesis of triglycerides and glycerophospholipids. The process by which these housekeeping lipids acquired functions as extracellular mediators remains a matter for debate and is discussed in further detail below. Separation of the synthesis, actions and inactivation of signaling LPA from the role of this lipid in intracellular metabolism is accomplished by physical and functional compartmentalization of the relevant enzymes and receptors. The molecular species diversity of LPA is considerably more complex than S1P because of variations in the chain length, saturation, and linkage of the radyl hydrocarbon substituent ( Figure 1 ). In particular, LPA species containing an ether-substituted hydrocarbon chain, which are more properly referred to as alkyl glycerol phosphates, have potent effects at particular LPA receptors, suggesting that structural diversity in this class of molecules may have important biological consequences. Plasmalogen LPA species and cyclic phosphatidic acid have also been reported in mammalian systems. The latter molecule, which may be formed by intramolecular transphosphatidylation catalyzed by intracellular phospholipase D, is particularly intriguing but relatively understudied.
Pathways for Synthesis, Signaling, and Degradation of LPA
Physiologically relevant levels of LPA can be detected in a variety of biological fluids, including the blood, most convincingly using high-performance liquid chromatography and tandem mass spectrometry methods, which have been reported by several groups. 3 LPA in blood plasma is predominantly bound to serum albumin 4 and can also be detected in lipoprotein fractions in contrast to S1P, which is predominantly associated with lipoproteins and may be carried specifically by HDL-associated apolipoprotein M. 5 Studies using stable or radioactive isotope-labeled tracers reveal that intravenously administered LPA is rapidly eliminated from the circulation, 6, 7 which at least in mice can be accounted for by a process involving rapid uptake in the liver. 8 This observation, coupled with observations that plasma LPA levels decline with similar rapidity after pharmacological inhibition of plasma LPA synthesis, has led to the conclusion that LPA undergoes rapid turn-over in the circulation. March 2014 gene have been inconclusive, the relative contributions of different cell types as sources for circulating ATX are presently unclear. A particularly interesting possibility is that adipocytes are a major source of circulating ATX. Cultured adipocytes express and release ATX, and circulating LPA and ATX levels in humans are correlated positively with body mass index. [13] [14] [15] Furthermore, mice lacking ATX in adipose tissue have reduced plasma ATX and LPA levels. 16 Conversely, ATX in adipose tissue and ATX and LPA in plasma increase in mice after being fed a high-fat diet 16 (Fanmuyi Yang and Susan S. Smyth, unpublished observations, 2013) . Lysophospholipids, most prominently LPC, are abundant in plasma and associated with plasma lipoproteins. Although it can be generated as a byproduct of cholesterol esterification in the liver, LPC can also be formed by the action of A-type phospholipases, which are present in plasma and released during platelet activation. 17, 18 We and others have shown that ATX binds blood and vascular cell integrins and that the interaction may be important for localized generation of LPA and targeting the enzyme to the surface of cells to produce cell-specific responses. [19] [20] [21] Thus, in addition to being present in plasma, LPA can also be generated dynamically in the vicinity of blood and vascular cells through regulated mechanisms involving cell surface recruitment of ATX. The effects of extracellular LPA are largely mediated by members of a family of G-protein-coupled receptors with ≥6 bona fide members (LPA 1-6 receptors). 1, 2, 22 In addition, LPA binds with high affinity to the immunoglobulin family receptor for advanced glycan endproducts, which may also contribute to cell-surface receptor-mediated LPA signaling. 23 Recombinant LPA receptors exhibit different selectivity for LPA species but how the molecular species diversity of LPA influences biological responses is not well understood. As mentioned above, LPA is also an obligatory intermediate in intracellular phospholipid synthesis and intracellular LPA generated by the glycerol-3-phosphate pathway, or perhaps cyclic phosphatidic acid formed by phospholipase D may signal via nuclear peroxisome proliferator receptor γ. 24, 25 Almost every subtype of primary or cultured blood and vascular cells exhibits some type of response to LPA and ATX. For example, LPA triggers vascular smooth muscular cell dedifferentiation and (because LPA is present in serum at high concentrations) may be a key factor in the serum response for phenotypic modulation of vascular smooth muscular cells. [26] [27] [28] LPA, a potent trigger for Rho activation, promotes endothelial cell migration and has been associated variably with increasing or decreasing endothelial barrier function, with most of the reports supporting the latter response. [29] [30] [31] ATX expression in endothelial cells can be elicited by vascular endothelial growth factor, [32] [33] [34] [35] and exposure to ATX increases angiogenesis into Matrigel implants. 32 LPA downregulates endothelial CD36 and may thereby blunt the inhibitory effects of thrombospondin on angiogenesis. In addition to promoting inflammatory responses on endothelial cells and leukocytes, [36] [37] [38] LPA triggers neutral lipid accumulation in monocytes. 39 LPA is a weak platelet activator 40 but potently stimulates fibronectin-matrix assembly on platelets, 41 a process that may be important for enhancing thrombus formation.
A role for ATX in vascular development has been established in zebrafish and mice. In mice, inherited deficiency of Enpp2-encoding ATX results in embryonic lethality, in part, because of failure of formation of yolk sac and embryonic vasculature. 11, 12 The zebrafish genome contains ATX paralogs with high homology to the mammalian protein and lysoPLD activity capable of generating LPA in vitro. 42 Zebrafish embryos injected with antisense morpholino oligonucleotides that target expression of ATX display vascular defects, in particular incomplete formation of the intersegmental vessels that sprout from the dorsal aorta. 42 The phenotype was recapitulated in morphant embryos targeting both LPA receptors 1 and 4, suggesting that these receptors are mediators of LPA-dependent effects of ATX that are required for proper vascular endothelial cell migration during vascular development.
The phenotype of mice lacking individual LPA receptors or some combinations of these receptors, is not as striking as that observed in Enpp2 -/animals. 1, 43 A subset of Lpar4 -/mice on a C57Bl/6 background exhibit embryonic lethality in association with edema and hemorrhage. 44 Angiogenesis in Matrigel implants is impaired in adult Lpar4 -/mice, suggesting that LPA 4 receptor may account for at least a portion of the LPA/ATX signaling necessary for postdevelopment blood vessel formation in these animals. Some Lpar1 -/mice develop frontal hematomas, but this phenotype is not exacerbated by combined deficiency of both Lpar1 and Lpar2. 45 Local infusion of LPA and, more markedly, alkylglycerolphosphate in the ligated carotid arteries of rats and mice elicits the development of neointimal hyperplasia. 46 In mice, this response is attenuated by genetic deficiency of Pparγ -/but not of LPA receptors 1 and 2, which is paradoxical because other genetic and pharmacological data identify a normally protective role for peroxisome proliferator receptor γ in models of vascular injury and atherosclerosis. 47, 48 We and others have reported that mice, lacking combinations of LPA receptors 1 to 3, display alterations in response to vascular injury and subsequent vessel remodeling. 49, 50 In our hands, the lack of LPA1 receptor exaggerated the positive remodeling response in injured femoral arteries. Interestingly, a similar phenotype of excessive vascular remodeling is observed in mice lacking Gα 12 /Gα 13 or their effector, the RhoGEF protein leukemia-associated Rho GEF. 51 Taken together, these observations underscore the complex interactions between receptors mediating LPA-dependent signaling responses in the vasculature where a combination of apparent redundancy (and perhaps compensatory changes in response to genetic deficiency of ≥1 of these receptors) continues to make it challenging to ascribe vascular signaling responses to particular LPA receptor classes or subtypes.
The signaling actions of LPA can be terminated by removal of the phosphate group, which generates the corresponding alcohols that are no longer agonists for LPA receptors. In mammals, lipid phosphate phosphatases (LPPs) constitute a family of 3 enzymes that dephosphorylate a broad range of lipid phosphates, including LPA and S1P, and these enzymes are members of a larger family of integral membrane enzymes with intra and extracellular roles in lipid metabolism and signaling. [52] [53] [54] [55] LPPs are encoded by the PPAP2 genes: LPP1 by the PPAP2A gene, LPP2 by the PPAP2C gene, and LPP3 by the PPAP2B gene. 56 LPPs localize to both the plasma membrane and to intracellular membrane organelles, in particular the endoplasmic reticulum and Golgi apparatus. 54, 56, 57 They are predicted to have a core of 6 transmembrane spanning helical regions with the N and C termini in the cytoplasmic side of the membrane. Based on this predicted topology and biochemical analysis, the active site of these enzymes is oriented on the extracellular (or luminal) face of the membrane.
Although the 3 LPP enzymes demonstrate similar catalytic activities and substrate preferences in vitro, the phenotypes of mice with targeted inactivation of the Ppap2 genes imply that they have nonredundant functions both during development and after birth. Mice with deficiency of Ppap2c 58 or harboring an exon trap inactivated allele of Ppap2a that results in mosaic hypomorphism for LPP1 appear phenotypically normal although the latter animals were reported to have higher plasma LPA levels. 7 In contrast, Ppap2b -/embryos are not viable and display defects in extraembryonic vascular development. 59 Media from Ppap2b-null mouse embryonic fibroblasts contain 2.6-fold higher levels of LPA than is found in media from wild-type cells. Using mice with tissue-specific inactivation of Ppap2b, we observed that LPP3 functions as an intrinsic negative regulator of smooth muscular cell function. 60 Studies of cultured aortic smooth muscular cells indicate that increased LPA accumulation and signaling may account, at least in part, for differences in Ppap2b -/--deficient cells. Results in endothelial-specific knockdown mice also support a role for LPP3 in maintaining vascular integrity both during development and postnatally. The ability of ATX inhibitors and LPA receptor antagonists to blunt the phenotype observed in Ppap2b-null mice indicates that enhanced LPA signaling may partially account enhanced permeability.
LPA Accumulates in Atherosclerotic Plaque and May Promote Experimental Atherosclerosis
Human atheroma contains higher levels of LPA than are found in normal healthy blood vessels, and LPA accumulates predominantly in the lipid-rich core. 61 Multiple LPA species can be detected by mass spectrometry-based analysis of lipid extracts from human and induced murine atheromas, and atheroma-associated LPA was suggested to play a role in platelet activation after plaque rupture. 62 Consistent with these observations, plaque-associated LPA was visualized in the core of atheromas by time of flight, single ion mass spectrometry in carotid arteries from Ldlr -/mice after Western diet feeding and collar placement. 63 In advanced lesions in Ldlr -/mice, LPA levels increase ≈20-fold with a particularly prominent accumulation of unsaturated long-chain acyl-LPA species. The changes in LPA levels in plaque are paralleled by alterations in enzymes that generate LPA and in LPA receptors. 64 However, at present the precise pathway(s) for LPA generation in atherosclerotic lesions (in particular the relative contributions of LPA generation in situ versus accumulation of LPA from circulating sources) are not known. In support of the concept that LPA present in plaques may have proatherosclerotic, proinflammatory, and prothrombotic effects, exogenous administration of LPA heightens atherosclerotic plaque burden in Apoe -/mice in an LPA 1 -and LPA 3 -receptordependent manner. 65 In addition, perivascular administration of LPA promotes the recruitment of inflammatory cells, in particular mast cells, to atherosclerotic plaques in carotid arteries and resulted in intraplaque hemorrhage. 63 Sampling of blood from coronary arteries at the time of acute myocardial infarction reveals higher local levels of LPA, which correlate with markers of platelet activation such as sCD40L. 66 Hyperlipidemia may also increase steady-state levels of LPA in plasma and enhance the capacity for LPA synthesis. Studies in rabbits suggest that systemic LPA levels may be influenced by cholesterol feeding, which elevates plasma lysophophosphatidyl choline levels and heightens the generation of LPA in serum. 67 Recent work suggests a link between levels of LPA in small intestine and experimental atherosclerosis. Feeding mice a diet supplemented with unsaturated LPA mimicked the inflammatory effects of a Western diet. 68 Interestingly, the effects of the LPA diet could be blocked by an apolipoprotein AI mimetic peptide 6F, which binds with high affinity to LPA and potently reduces atherosclerosis in Ldlr -/mice. [69] [70] [71] Together, these findings support the contention that LPA is positioned to play a central role in atherothrombotic disease. 71 However, generation of definitive data on the role of LPA in experimental models of atherosclerosis has been hampered by redundancy among LPA receptors, obligatory roles for genes encoding enzymes that generate and inactivate LPA in early development, and a lack of potent selective small molecules targeting these receptors and enzymes. Several promising experimental therapeutics that target the ATX/LPA nexus have been reported recently and should provide tools to establish a role in atherosclerosis in both animals and potentially in humans.
Association of a Common Polymorphism in PPAP2B With Human Coronary Artery Disease
The evidence described in the preceding paragraphs strongly supports a role for LPA and its G-protein-coupled receptors in the development of experimental atherosclerosis in animal models. Investigation of the genetics of coronary artery disease (CAD) in humans suggests that the findings in mice may be translatable. Approximately 60% of the interindividual variability in cardiovascular disease risk in humans is estimated to be heritable. Genome-wide association studies 72 and a meta-analysis of genome-wide association studies identified heritable single nucleotide polymorphisms (SNPs) in the PPAP2B gene encoding LPP3 as novel loci associated with CAD susceptibility. 73 In the meta-analysis of >86 000 individuals, the PPAP2B locus independently predicted CAD (odds ratio, 1.17; P=3.81×10 -19 ) and lacked association with traditional risk factors such as hypertension, cholesterol, diabetes mellitus, obesity, or smoking. The major risk allele, rs17114036 allele, is located in the final intron of the 6 exon PPAP2B gene. At least 7 SNPs are in robust linkage disequilibrium (r 2 >0.9) with rs17114036. 74 Although data for rs17114036 are not available in publicly accessible data sets, query of the SNPExpress database for the proxy SNP rs9970807 (r 2 of 0.901 with rs17114036) predicts that the major risk-associated allele is associated with lower leukocyte mRNA expression for most of the PPAP2B exons, and 2 other proxy SNPs show similar patterns. Overall, these results suggest that the major allele of rs9970807 and therefore rs17114036 might be associated with decreased expression of LPP3 protein. To characterize the role of candidate genes in atherosclerosis, Erbilgin et al 75 performed expression quantitative locus mapping in endothelial cells and observed an upregulation of Ppap2b expression in aortic endothelial cells isolated from 4-week-old Apoe −/− mice and in atherosclerotic lesions obtained from 24-week-old Apoe −/− mice. Taken together, these observations support the testable hypothesis that LPP3 serves to suppress atherosclerosis and stabilize atherosclerotic plaques and that individuals with diminished LPP3 expression are at heightened risk for the development and complications of atherosclerosis. Ongoing and published studies support a role for LPP3 as a negative regulator of LPA signaling, likely by counteracting localized LPA synthesis or decreasing extracellular LPA levels. Evidence for effects of LPPs on both cell-specific and cell-autonomous signaling responses comes from studies in Drosophila development in which expression of LPPs encoded by the 2 wunen genes in both somatic and germ cells is necessary for proper germ-cell guidance and survival in the developing embryo. 76 Because wunen mutations can be complemented by mammalian LPP3, it seems likely that LPP3 expression in mammalian systems will also result in a combination of cell-specific and cell-autonomous effects on lipid mediator production and signaling. For example, in the complex setting of atherosclerosis, cardiovascular disease risk-associated alterations in expression of LPP3 in vascular endothelial cells, vascular smooth muscle cells, and monocytes might result in heightened cell-specific signaling responses to LPA during lesion formation, as well as cell-type independent increases in accumulation of LPA in the developing atheroma. If the primary mechanism accounting for alterations in expression of LPP3 on human cardiovascular disease risk stems from a role of this enzyme in attenuating cell-type-specific LPA signaling responses or accumulation of LPA in vascular lesions, then pharmacological approaches that inhibit ATX activity or block the signaling responses mediated by LPA receptors would also be expected to reduce atherosclerosis in humans. These ideas also support the view that adipose-derived ATX could serve as a novel mediator of accelerated atherosclerosis that is associated with obesity ( Figure 2 ). However, it is important to note that additional non-LPA-dependent mechanisms could contribute to a role for LPP3 in limiting atherosclerosis. For example, LPP3 also hydrolyses S1P and changes in S1P signaling could affect vessel responses to injury. LPP3 may 77 also have roles in regulating intracellular lipid metabolism and signaling that are not directly related to effects on cell surface receptor-mediated LPA responses. LPP3 has also been suggested to have nonenzymatic functions that may be mediated by integrin binding or catenin signaling. 59, 78, 79 Notwithstanding these caveats, determining the mechanism by which the risk-associated allele of PPAP2B predicts CAD risk is now an important goal to both validate this new genetic marker as a biomarker of disease risk and provide insights into the basic mechanisms of CAD that may be used to improve therapeutic strategies to prevent its development and complications.
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A significant proportion of the risk of coronary artery disease is inherited. Efforts to understand the genetic basis of coronary artery disease have revealed a potential role for lysophospholipid signaling in the development and complications of atherosclerosis. Growing evidence from experiment model systems supports a role for the autotaxin, lysophosphatidic acid, lipid phosphate phosphatase 3 system in regulating molecular events that may control blood and vascular cell involvement in atherosclerosis.
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Insight into the Author: Susan S. Smyth, MD, PhD, University of Kentucky Why did you choose the profession of scientific investigation?
According to my mother, I was always very curious as a child, bringing creatures such as snakes and frogs into the house and putting them in the bathtub to watch. In high school, I had a fantastic AP biology course that first opened my eyes to science. I entered college with the intent of being a biology major, and my enthusiasm for science grew at Mount Holyoke. Ultimately, I decided that pursuing dual MD and PhD training would provide me with the broadest possible education. During my clinical training, abciximab received approval as adjunctive therapy for angioplasty. Having used the parent molecule monoclonal antibody 7E3 in experiments as a graduate student, it was a careerchanging experience to administer abciximab to patients. That is when I realized that a career in cardiovascular medicine was my future.
Who have been your role models in your scientific and professional life?
I have been incredibly fortunate to have had the opportunity to work with several talented physicians and scientists who possess true generosity of spirit-too many to list in a brief space. My most influential professional role models were my doctoral and fellowship mentors, Leslie Parise, who is now Chair of biochemistry at the University of North Carolina, and Barry Coller, then chairman of medicine at Mount Sinai Medical Center and currently physician-in-chief at Rockefeller University. Leslie has this unwavering optimism about everything-she is the type of scientist who gets excited by 6 months of work that fails to show an effect. Having a tenacious, driven, enthusiastic mentor made me eager to work in the laboratory as a graduate student. Working with Barry later in my training convinced me that a career as a physician-scientist was not only possible but right for me. Still today, he stands as the embodiment of innovation, creativity, and spirit of the ideal physician-scientist. In addition to his numerous scientific accomplishments, he routinely writes with profound insight on contemporary issues and challenges in medicine. Leslie and Barry taught me the power of the scientific method, encouraged my curiosity, and provided their unwavering support. I would be remiss if I did not mention the physicians in the thrombosis and hemostasis group in Chapel Hill, including Harold Roberts and Gill White, and the vascular biology group and Mark Taubman at Mount Sinai, who were tremendously influential as role models. Finally, the person who has single-handedly sustained my enthusiasm for research is my husband with his encouragement and passion for science.
Which direction do you envisage your science taking?
I am amazed at how advances in technology are exponentially driving science. Projects that would have taken an entire graduate student career when I started in science can now be completed in hours. To take full advantage of what is available, laboratories and groups have to collaborate across disciplines. As an MD/PhD, my goal has been to have an effect on human health and disease. When I started, I thought that would ultimately require me to transition from academics to industry. However, in the past several years, our group has taken on more clinical and translational directions and increasingly collaborates with other groups in the United States and abroad. I now see the possibility of moving beyond bench-to-bedside into population science and a role for science in public policy and educational efforts.
What are your nonscientific activities?
Most of my time outside of work is spent with our 2 sons, William and Edward, ages 11 and 14 years. The boys and I often cook or garden together. In the past year, we planted nearly a thousand daffodil bulbs on our 2-acre property in the heart of horse country. We have an amazing view from our home-rolling pastures, barns, black-board fencing, and incredible thoroughbreds all right in our backyard. We cannot wait for the added color from the bulb blooms in the spring.
